Wells Fargo Initiates Coverage of iTeos Therapeutics (ITOS) with ...

Aug 6, 2024 · Fintel reports that on August 13, 2024, Wells Fargo initiated coverage of iTeos Therapeutics (NasdaqGM:ITOS) with a Overweight recommendation. Analyst Price Forecast …

$31.00
OFF

ITeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought By

1 week from now

Nov 27, 2024 · Wells Fargo & Company initiated coverage on shares of iTeos Therapeutics in a research note on Tuesday, August 13th. They issued an "overweight" rating and a $31.00 …

marketbeat.com

$19
OFF

ITeos Therapeutics Price Target Lowered To $19 From $31 At Wells …

1 week from now

Dec 20, 2024 · Wells Fargo lowered the firm’s price target on iTeos Therapeutics (ITOS) to $19 from $31 and keeps an Overweight rating on the shares. The firm adjusted price targets in the …

yahoo.com

$113000
OFF

Quest Partners LLC Has $113,000 Holdings In ITeos Therapeutics, …

1 week from now

Nov 30, 2024 · Finally, Wells Fargo & Company initiated coverage on iTeos Therapeutics in a report on Tuesday, August 13th. They set an “overweight” rating and a $31.00 price objective …

etfdailynews.com

$46.00
OFF

Dimensional Fund Advisors LP Raises Position In ITeos …

1 week from now

Oct 6, 2024 · HC Wainwright reissued a "buy" rating and issued a $46.00 price target on shares of iTeos Therapeutics in a report on Monday, September 16th. Finally, Wells Fargo & Company …

marketbeat.com

$31
OFF

Wells Fargo Initiates Coverage On ITeos Therapeutics With …

1 week from now

Aug 13, 2024 · Wells Fargo analyst Eva Fortea Verdejo initiates coverage on ITeos Therapeutics (NASDAQ:ITOS) with a Overweight rating and announces Price Target of $31.

sahmcapital.com

$31.00
OFF

ITeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Acquired By …

1 week from now

Dec 20, 2024 · Wells Fargo & Company reduced their price objective on iTeos Therapeutics from $31.00 to $19.00 and set an “overweight” rating for the company in a research note on …

americanbankingnews.com

$8.73
OFF

Iteos Therapeutics Stock Hits 52-week Low At $8.73 - Investing.com

1 week from now

Oct 23, 2024 · In analyst coverage, JPMorgan, Piper Sandler, and H.C. Wainwright have maintained their Overweight and Buy ratings on iTeos shares, while Wells Fargo initiated an …

investing.com

$31.00
OFF

Matthew Gall Acquires 5,000 Shares Of ITeos Therapeutics, Inc.

1 week from now

Nov 20, 2024 · Wells Fargo & Company assumed coverage on iTeos Therapeutics in a research report on Tuesday, August 13th. They set an "overweight" rating and a $31.00 price objective …

insidertrades.com

$31.00
OFF

H.C. Wainwright Maintains Buy Rating On ITeos Shares On ESMO Data

1 week from now

Sep 16, 2024 · In analyst coverage, Wells Fargo initiated an Overweight rating on iTeos Therapeutics, setting a price target of $31.00. Similarly, H.C. Wainwright reaffirmed a Buy …

investing.com

06%
OFF

Wells Fargo & Company Issues Pessimistic Forecast For ITeos ...

1 week from now

Dec 21, 2024 · Wells Fargo & Company‘s target price would indicate a potential upside of 156.06% […] iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) had its price objective …

etfdailynews.com

FAQs about Wells Fargo Initiates Coverage of iTeos Therapeutics (ITOS) with ... Coupon?

Is iTeos Therapeutics (Itos) a good stock to buy?

iTeos Therapeutics (NASDAQ:ITOS – Get Free Report) had its price objective reduced by equities research analysts at Wells Fargo & Company from $31.00 to $19.00 in a report issued on Thursday, Benzinga reports. The firm presently has an “overweight” rating on the stock. ...

What is the average price target for iTeos Therapeutics?

As of August 6, 2024, the average one-year price target for iTeos Therapeutics is $38.25/share. The forecasts range from a low of $21.21 to a high of $49.35. The average price target represents an increase of 163.79% from its latest reported closing price of $14.50 / share. See our leaderboard of companies with the largest price target upside. ...

How many funds own iTeos Therapeutics (ITOS)?

There are 312 funds or institutions reporting positions in iTeos Therapeutics. This is an decrease of 20 owner (s) or 6.02% in the last quarter. Average portfolio weight of all funds dedicated to ITOS is 0.11%, an increase of 4.51%. Total shares owned by institutions increased in the last three months by 1.57% to 36,604K shares. ...

How much will iTeos Therapeutics earn per share?

On average, equities research analysts forecast that iTeos Therapeutics will post -3.46 earnings per share for the current fiscal year. In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. ...

Who owns iTeos Therapeutics?

Virtu Financial LLC bought a new position in iTeos Therapeutics in the third quarter worth about $102,000. Finally, Quest Partners LLC raised its stake in iTeos Therapeutics by 914.7% in the third quarter. Quest Partners LLC now owns 11,020 shares of the company’s stock worth $113,000 after buying an additional 9,934 shares in the last quarter. ...

How much did Matthew Gall buy iTeos Therapeutics stock?

In other iTeos Therapeutics news, CFO Matthew Gall bought 5,000 shares of iTeos Therapeutics stock in a transaction dated Tuesday, November 19th. The shares were purchased at an average cost of $7.73 per share, with a total value of $38,650.00. ...